Enovis (NYSE:ENOV) PT Lowered to $62.00

Enovis (NYSE:ENOV) had its price target decreased by Evercore ISI from $70.00 to $62.00 in a report released on Tuesday, Benzinga reports. Evercore ISI currently has an outperform rating on the stock.

ENOV has been the subject of a number of other research reports. Needham & Company LLC reiterated a buy rating and set a $82.00 price objective on shares of Enovis in a research report on Friday, May 3rd. JPMorgan Chase & Co. started coverage on Enovis in a report on Thursday, June 13th. They set a neutral rating and a $53.00 target price on the stock. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Enovis presently has a consensus rating of Moderate Buy and an average price target of $71.44.

Enovis Price Performance

Shares of ENOV opened at $44.44 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.03 and a current ratio of 2.10. Enovis has a fifty-two week low of $43.04 and a fifty-two week high of $66.14. The firm has a 50-day simple moving average of $48.71 and a 200-day simple moving average of $55.48. The company has a market capitalization of $2.44 billion, a price-to-earnings ratio of -29.63 and a beta of 1.92.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.50. Enovis had a positive return on equity of 3.98% and a negative net margin of 4.51%. The company had revenue of $516.00 million during the quarter, compared to analysts’ expectations of $505.62 million. During the same period last year, the firm earned $0.44 EPS. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. On average, equities research analysts anticipate that Enovis will post 2.62 earnings per share for the current year.

Institutional Trading of Enovis

Hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN grew its holdings in shares of Enovis by 907.7% in the 4th quarter. Wells Fargo & Company MN now owns 559,430 shares of the company’s stock worth $31,339,000 after acquiring an additional 503,913 shares during the last quarter. Channing Capital Management LLC boosted its holdings in Enovis by 26.6% during the fourth quarter. Channing Capital Management LLC now owns 1,588,417 shares of the company’s stock valued at $88,983,000 after acquiring an additional 334,154 shares during the period. UBS Group AG grew its position in shares of Enovis by 1,060.8% in the fourth quarter. UBS Group AG now owns 333,510 shares of the company’s stock valued at $18,683,000 after purchasing an additional 304,779 shares during the last quarter. DAVENPORT & Co LLC boosted its stake in Enovis by 12.6% during the 4th quarter. DAVENPORT & Co LLC now owns 1,879,425 shares of the company’s stock valued at $105,920,000 after purchasing an additional 210,358 shares during the period. Finally, Boston Partners lifted its holdings in shares of Enovis by 206.5% during the first quarter. Boston Partners now owns 295,969 shares of the company’s stock worth $18,455,000 after buying an additional 199,411 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.